• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[人血浆中激肽释放酶、纤溶酶及凝血酶前体和抑制剂的同步测定方法]

[Method of simultaneous determination of kallikrein, plasmin and thrombin precursors and inhibitors in human blood plasma].

作者信息

Gomazkov O A, Komissarova N V

出版信息

Biull Eksp Biol Med. 1976 May;81(5):632-4.

PMID:132976
Abstract

Prekallikrein, plasminogen and prothrombin of human blood plasma have been separately activated by caolin streptokinase and thromboplastin. By measuring the TAME-esterase (N-d Tozy-L-arginine methyl ester) activity of each enzyme and its changes in the course of plasma incubation with the activator, it was possible to estimate the values of precursors of kallikrein, plasmin, thrombin and their inhibitors. Evidence is given that under conditions described the activation is specific of each enzyme and does not affect the level of the two other percursors. The method has been developed in two modifications, permitting to obtain the value of seven parameters in 0.4--0.7 ml of blood plasma.

摘要

人血浆中的前激肽释放酶、纤溶酶原和凝血酶原已分别被高岭土链激酶和凝血活酶激活。通过测量每种酶的TAME酯酶(N-d-对甲苯磺酰-L-精氨酸甲酯)活性及其在血浆与激活剂孵育过程中的变化,可以估算激肽释放酶、纤溶酶、凝血酶及其抑制剂前体的值。有证据表明,在所述条件下,激活对每种酶具有特异性,并且不影响其他两种前体的水平。该方法已开发出两种改进形式,能够在0.4 - 0.7毫升血浆中获得七个参数的值。

相似文献

1
[Method of simultaneous determination of kallikrein, plasmin and thrombin precursors and inhibitors in human blood plasma].[人血浆中激肽释放酶、纤溶酶及凝血酶前体和抑制剂的同步测定方法]
Biull Eksp Biol Med. 1976 May;81(5):632-4.
2
[Relationship between the activity of the kallikrein, plasmin and thrombin systems of the blood during intense physical exertion].[剧烈体力活动期间血液中激肽释放酶、纤溶酶和凝血酶系统活性之间的关系]
Biull Eksp Biol Med. 1977 Nov;84(11):521-3.
3
[Levels of kallikrein, plasmin and thrombin precursors and the activity of their inhibitors in hypertension patients].[高血压患者中激肽释放酶、纤溶酶和凝血酶前体水平及其抑制剂活性]
Vrach Delo. 1985 Aug(8):37-40.
4
Development of plasma kallikrein selective inhibitors.血浆激肽释放酶选择性抑制剂的研发。
Biopolymers. 1999;51(1):41-50. doi: 10.1002/(SICI)1097-0282(1999)51:1<41::AID-BIP5>3.0.CO;2-Y.
5
Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.选择S18326作为一种新型强效且选择性的硼酸直接凝血酶抑制剂。
Thromb Haemost. 1997 Oct;78(4):1221-7.
6
Serine protease specificity for peptide chromogenic substrates.丝氨酸蛋白酶对肽类生色底物的特异性。
Thromb Haemost. 1977 Dec 15;38(4):776-92.
7
Plasma prekallikrein: quantitative determination by direct activation with Hageman factor fragment (beta-XIIa).血浆前激肽释放酶:通过与哈格曼因子片段(β - XIIa)直接激活进行定量测定。
J Lab Clin Med. 1983 Feb;101(2):226-41.
8
[Nature of the proteinase activated by the contact factor in human blood plasma].[人血浆中接触因子激活的蛋白酶的性质]
Vopr Med Khim. 1977 May-Jun(3):391-6.
9
Studies on assays for plasma prekallikrein and for the monitoring of coumarol therapy.血浆前激肽释放酶检测及香豆素治疗监测的研究。
Haemostasis. 1978;7(2-3):85-91. doi: 10.1159/000214240.
10
A novel chromogenic peptide for prekallikrein/kallikrein determination.一种用于检测前激肽释放酶/激肽释放酶的新型显色肽。
Clin Lab. 2009;55(3-4):106-13.